Durable Responses with ADP-A2M4 in Synovial Sarcoma with Confirmed Responses in 44% of Patients and Disease Control Rate of 9...
November 19 2020 - 9:00AM
Adaptimmune Therapeutics plc (Nasdaq: ADAP), a leader in cell
therapy to treat cancer, presented durability of response data from
patients with synovial sarcoma from the Phase 1 ADP-A2M4 trial at
the virtual Connective Tissue Oncology Society (CTOS) annual
meeting. The oral presentation given by Dr. Brian Van Tine of the
Washington University School of Medicine is available on-demand for
congress attendees. Dr. Van Tine will also participate in a “live
stream” session entitled - Immunotherapy in Sarcoma: Alveolar Soft
Part Sarcoma, Clear Cell Sarcoma, Synovial Sarcoma (Proffered
Papers Panel Discussion) scheduled for 9 AM EST today (November
19).
“The impact on patients treated with ADP-A2M4 is transformative,
as they benefit from a durable response from a single treatment.
This leads to the highest quality of life I have been able to
provide patients with synovial sarcoma after treatment,” said Dr.
Brian Van Tine, Associate Professor of Medicine, Division of
Oncology, Section of Medical Oncology, Washington University School
of Medicine.
“Data from this trial have enabled rapid execution of our
pivotal trial, SPEARHEAD-1, and support our aim to commercialize
ADP-A2M4 as the first engineered TCR T-cell product in the US in
2022,” said Adrian Rawcliffe, Adaptimmune’s Chief Executive
Officer. “However, this is only the beginning of the tremendous
potential of our products targeting MAGEA4. We will rapidly pursue
additional indications, starting with the Phase 2 trial in
gastroesophageal cancers with ADP-A2M4CD8 expected to initiate in
the first half of 2021.”
Data presented at CTOS were updated durability of response and
safety data from the 16 patients with synovial sarcoma who
were treated in the Phase 1 ADP-A2M4 trial, presented earlier this
year at ASCO. The data cut-off for this presentation was September
1, 2020 and results are summarized below:
- Seven out of 16 patients (44%) had confirmed partial responses
(PRs) per RECIST criteria, with disease control in 15 patients
(94%)
- There was a median duration of response of 28 weeks (range:
12-72+ weeks) with two PRs that were ongoing beyond 72 weeks at the
time of data cut-off
- Eleven out of 16 patients were alive at data cut-off and median
overall survival had not been reached
- Translational data indicate that induction of the IFNγ-related
pathway by serum analyses is an emerging biomarker of response.
MAGE-A4 expression and transduced cell dose correlate with tumor
reduction
- Most adverse events were consistent
with those typically experienced by cancer patients undergoing
lymphodepletion chemotherapy and cellular therapy including low
blood counts and cytokine release syndrome
About AdaptimmuneAdaptimmune is a
clinical-stage biopharmaceutical company focused on the development
of novel cancer immunotherapy products for people with cancer. The
Company’s unique SPEAR® (Specific Peptide Enhanced Affinity
Receptor) T-cell platform enables the engineering of T-cells to
target and destroy cancer across multiple solid tumors.
Forward-Looking StatementsThis release contains
“forward-looking statements” within the meaning of the Private
Securities Litigation Reform Act of 1995 (PSLRA). These
forward-looking statements involve certain risks and uncertainties.
Such risks and uncertainties could cause our actual results to
differ materially from those indicated by such forward-looking
statements, and include, without limitation: the success, cost and
timing of our product development activities and clinical trials
and our ability to successfully advance our TCR therapeutic
candidates through the regulatory and commercialization processes.
For a further description of the risks and uncertainties that could
cause our actual results to differ materially from those expressed
in these forward-looking statements, as well as risks relating to
our business in general, we refer you to our Quarterly Report on
Form 10-Q filed with the SEC on November 5, 2020, and our other SEC
filings. The forward-looking statements contained in this press
release speak only as of the date the statements were made and we
do not undertake any obligation to update such forward-looking
statements to reflect subsequent events or circumstances.
Media Relations:
Sébastien Desprez — VP, Communications and Investor RelationsT:
+44 1235 430 583M: +44 7718 453
176Sebastien.Desprez@adaptimmune.com
Investor Relations:
Juli P. Miller, Ph.D. — Senior Director, Investor RelationsT: +1
215 825 9310M: +1 215 460 8920Juli.Miller@adaptimmune.com
Adaptimmune Therapeutics (NASDAQ:ADAP)
Historical Stock Chart
From Aug 2024 to Sep 2024
Adaptimmune Therapeutics (NASDAQ:ADAP)
Historical Stock Chart
From Sep 2023 to Sep 2024